With the global market for asthma and COPD drugs set to reach $41.23bn in 2017, Asthma and COPD 2015 comes at the perfect time to explore the future of therapeutics, diagnosis and care.
Join us we ask questions such as: How is severe asthma in children pathophysiologically different to the adult disease? Is airway remodelling dependent on inflammation? What value can patient charities bring to multi-partner collaborations? What are the drug development challenges associated with inhaled and intranasal antivirals? What are the key areas of unmet clinical needs for COPD clinical care?
REASONS TO ATTEND
Explore the future of asthma and COPD treatment from a range of key perspectives
Discover advances in inhaled therapies
Discuss personalised therapy approaches, asthma patient stratification and unmet needs
Share in the latest thinking from the clinic to improve the lives of patients
Explore the latest thinking on biomarkers and clinical trial endpoints
Update on mechanisms and treatment for viral induced COPD and asthma exacerbations
KEY SPEAKERS INCLUDE:
Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London 鈥� Conference Chair
Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University 鈥� Conference Chair
Neil C Thomson, Professor of Respiratory Medicine, University of Glasgow
Joseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc.
Dirk Smith, Scientific Director, Amgen
U Roland Kolbeck, Senior Director, Respiratory, Inflammation and Autoimmunity, MedImmune
Hector Ortega, Medical Director, Respiratory RandD, GSK
Maria Buxton, Consultant Respiratory Physiotherapist, London North West Healthcare NHS Trust
Join us we ask questions such as: How is severe asthma in children pathophysiologically different to the adult disease? Is airway remodelling dependent on inflammation? What value can patient charities bring to multi-partner collaborations? What are the drug development challenges associated with inhaled and intranasal antivirals? What are the key areas of unmet clinical needs for COPD clinical care?
REASONS TO ATTEND
Explore the future of asthma and COPD treatment from a range of key perspectives
Discover advances in inhaled therapies
Discuss personalised therapy approaches, asthma patient stratification and unmet needs
Share in the latest thinking from the clinic to improve the lives of patients
Explore the latest thinking on biomarkers and clinical trial endpoints
Update on mechanisms and treatment for viral induced COPD and asthma exacerbations
KEY SPEAKERS INCLUDE:
Sebastian Johnston, Professor of Respiratory Medicine, National Heart and Lung Institute, Imperial College London 鈥� Conference Chair
Robert Niven, Senior Lecturer in Respiratory Medicine, Manchester University 鈥� Conference Chair
Neil C Thomson, Professor of Respiratory Medicine, University of Glasgow
Joseph Arron, Associate Director, Biomarker Discovery, Genentech, Inc.
Dirk Smith, Scientific Director, Amgen
U Roland Kolbeck, Senior Director, Respiratory, Inflammation and Autoimmunity, MedImmune
Hector Ortega, Medical Director, Respiratory RandD, GSK
Maria Buxton, Consultant Respiratory Physiotherapist, London North West Healthcare NHS Trust
